Patients with Type 2 (non-insulin-dependent) diabetes mellitus complicated by microalbuminuria or albuminuria, have an increased risk of developing macrovascular disease and of early mortality. Because lipoprotein abnormalities have been associated with diabetic nephropathy, this study tested the hypothesis that levels of apolipoprotein (a) are elevated in patients with Type 2 diabetes and increased levels of urinary albumin loss. Levels of apolipoprotein (a) in diabetic patients with microalbuminuria (n = 26, geometric mean 195 U/l, 95 % confidence interval 117-324) and albuminuria (n = 19, 281 U/l, 165-479) were higher than in nondiabetic control subjects (n = 140,107 U/l, 85-134,p < 0.05), and in the atbuminuric group than diabetic patients without urinary albumin loss (n = 58, 114 U/l, 76-169, p < 0.05). Patients with microalbuminuria and albuminuria had levels comparable with patients undergoing elective coronary artery graft surgery (n = 40,193 U/l, 126-298). Apolipoprotein (a) levels were higher in diabetic patients with macrovascular disease than in those without (n = 49, 209 U/l, 143-306 vs n = 54, 116 U/l, 78-173, p < 0.05). These preliminary results suggest that raised apolipoprotein (a) levels of Type 2 diabetic patients with microalbuminuria and albuminuria may contribute to their propensity to macrovascular disease and early mortality.
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There is evidence that microalbuminuria in Type 2 (noninsulin-dependent) diabetic patients predicts the development of proteinuria and early mortality [1, 2] . The excess morbidity and mortality of Type 2 diabetic patients is predominantly due to macrovascular disease, with renal failure accounting for only 3-5 % of total mortality [3, 4] . Potential contributory factors to the excess macrovascular disease include atherogenic changes in the lipid profile, increased blood pressure, hyperglycaemia, hyperinsulinaemia, obesity and alteration ofhaemostatic factors [3, 5] .
Lipoprotein (a) or Lp (a) is an independent risk factor for macrovascular disease, the levels of which are under strong genetic influence. Structurally it is a hybrid of low density lipoprotein (LDL) and a specific plasminogenlike glycoprotein apolipoprotein (a) or apo (a), which is attached to the apo B100 of LDL [6] . Recent reports have indicated that apo (a) levels are elevated in Type I (insulin-dependent) diabetic patients with microalbuminuria and albuminuria [7] [8] [9] . In this study we have investigated whether apo (a) levels are also raised in Type 2 diabetic patients with increased urinary albumin loss, which may contribute to the heightened risk of macrovascutar disease in these patients.
Patients and methods
Our study comprised 103 patients with Type 2 diabetes [10] attendiug the St Vincent's Hospital Diabetes Clinic. All subjects gave informed consent and the study was approved by the Human Research Ethics Committee at St Vincent's Hospital. Cigarette smokers were defined as current smokers or those having smoked more than one cigarette per day-within the previou~s 5 years. Macrovascular disease included ischaemic heart, peripheral vascular and cerebrovascular disease. Positive manifestations were a resting 12-lead ECG with evidence of infarction, or a history of anNna, myocardial infarction, transient ischaemic attack, stroke, intermittent claudication, rest pain, limb amputation or arterial surgery. All patients who had absent pedal pulses on examination also had other evidence of macrovascular disease. Patients with intercurrent conditions or taking medications that might influence apo (a) levels [11] [12] [13] [14] were excluded from sampling.
Urine collections were analysed for albumin (rate nephelometr~; coefficient of variation, CV < 5 %), total protein and creatinine. The mean concentration from two overnight 12-h urine collections performed on consecutive days, not after heavy exercise, was taken. The Type 2 diabetic population was subdivided according to the level of urinary albumin loss: less than or equal to 20 gg/min, no microalbuminuria, between 21 and 200 gg/min, microalbuminuria, and greater than 200 gg/min, albuminuria. After a 10 to 12 h overnight fast 10 ml ofbloodwas taken by venepunctureinto an EDTAtube for lipid anal- yses and 10 ml into a lithium heparin tube for other measurements. Parameters assayed were HbAI~, total cholesterol, triglyceride, HDL cholesterol, total protein, albumin and creatinine. Apo (a) was measured by immunoradiometric assay (Pharmacia, Uppsala, Sweden) as described previously [7] . LDL cholesterol was calculated using a modification of the Friedewatd equation that corrects for the cholesterol content of Lp (a).The formulaused [12] was: LDL (mmol/1)=total cholesterol -HDL cholesterol-triglyceride/2.2 -Lp (a) (mg/1) x 0.3/386.7, assuming that 1 U/1 apo (a) = 1 rag/1Lp (a).
Apo (a) levels were also determined in a control population of 140 non-diabetic apparently healthy hospital staff members (62 men and 78 women), of whom 44 had fasted for 10-12 h. In addition apo (a) was measured in fasting blood samptes from 40 consecutive non-diabetic men about to undergo elective coronary artery graft surgery for angiographically diagnosed coronary artery disease. Apo (a) levels in these different groups can be compared as age, gender, body mass index and prandial status do not influence apo (a) levels [12] [13] [14] [15] . The predominant ethnic background of all study subjects was Caucasian [16] .
Statistical analysis
Statistical analyses were performed using the MINITAB (Minitab Inc., State College, Pa., USA) STATVIEW and SUPERANOVA (Abacus Concepts, Berkeley, Calif., USA) statistical packages.
Skewed distributions were first normalized using square root or logarithmic transformations. Analysis of variance was used to compare continuous variables and the chi square test to compare discontinuous variables between groups. Correlations between normalized variables were tested by the Pearson correlation test.
Results
Characteristics of the Type 2 diabetic population divided according to urinary albumin loss are shown in Tables 1  and 2 . As shown in Figures 1 and 2 , apo (a) levels were increased in the Type 2 diabetic patients in the microalbuminuria group (geometric mean 195 U/l, 95 % confidence interval 117-324) and albuminuria group (281 U/l, 165-479) relative to control subjects (107 U/l, 85-134) and in the albuminuric group relative to diabetic patients without microalbuminuria (114 U/l, 76-169). Apo (a) levels in the diabetic microalbuminuria and albuminuria groups were comparable with those of the non-diabetic patients undergoing coronary artm 7 graft sm'gery (193 U/l, 126-298). Apo (a) levels were higher in Type 2 diabetic patients with macrovascular disease (n = 49, 209 U/l, 143-306) than in those without (n =54, 116U/1, 78-173, Apo(a), U/I p < 0.05). This finding was independent of urinary albumin loss grouping as determined by two factor analysis of variance. In the Type 2 diabetic patients log apo (a) correlated with age (r = 0.234, p < 0.05) and with log plasma creatinine (r = 0.327, p < 0.001). However, tog plasma creatinine correlated with age (r = 0.234, p < 0.05) and when these two variables were used in multiple regression analysis, age was no longer a significant predictor. There was a negative relationship between log apo (a) and the square root of creatinine clearance (r :-0.188), which was not statistically significant (0.10>p >0.05). There was no correlation between log apo (a) and the amount of urinary protein or albumin loss.
Analysis of variance and covariance were also used to explore the determinants of log apo (a) values. Single significant factors included urinary albumin grouping (Fisher distribution value [F] = 3.57,p < 0.05), and the covariate log plasma creatinine (F = 11.64, p < 0.001). Plasma protein was not significant as a single covariate (F = 2.18, p > 0.05), although it was significant when included in the model with log plasma creatinine (log plasma creatinine F=13.76, p <0.001, plasma protein F= 4.71,p <0.05).
Discussion
We have demonstrated increased apo (a) levels in a limited number of Type 2 diabetic patients with microalbuminuria and albuminuria relative to non-diabetic control subjects, and in the albuminuric group relative to diabetic patients without urinary albumin loss. Elevation of Lp (a) with hyperglycaemia has been reported for Type 1 [16, 17] but not Type 2 diabetes [18] . We found no relationship between glycaemic control and level of apo (a) in this study. Consistent with the proposed role for Lp (a) as an atherogenic particle, apo (a) levels were higher in Type 2 diabetic patients with macrovascular disease than in those without, independent of urinary albumin loss. Similar findings have been reported previously for predominantly non-diabetic subjects [19] , although a recently reported prospective study did not show any association between coronary heart disease mortality and Lp (a) in a small number of patients with Type 2 diabetes [20] .
Elevated apo (a) or Lp (a) levels have been shown to be associated with coronary artery disease, cerebral infarction, cervical atheroma, aortic aneurysms and peripheral vascular disease [21] [22] [23] [24] [25] . One mechanism by which Lp (a) could accelerate atherosclerosis is by penetration into the arterial wall [21, 25, 26] . Another possible atherogenic effect is attenuation of clot lysis due to competi- 
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Non-Ma Ma AIb CAG Fig. 2 . Geometric mean and 95 % confidence intervals of the control subjects (n = 140), patients with Type 2 (non-insulin-dependent) diabetes divided according to urinary albumin loss (non-microalbuminuric, Non-Ma, n =58; microalbuminuric, Ma, n =26; albuminuric, Alb, n = 19) and coronary artery graft patients (CAG, n = 40). Apolipoprotein (a) [apo (a)] levels were compared by analysis of variance. * p < 0.05 vs control subjects;¢ p < 0.05 vs Non-Ma patients tive binding of apo (a) to plasminogen receptors on the vascular endothelium, reducing activation of plasminogen by tissue plasminogen activator [21, 27] . Thus, elevated apo (a) may be an important factor in the observed link between microalbuminuria, macrovascular disease and early mortality in Type 2 diabetic patients [1] . Prospective studies will be necessary to define the importance of this association. Diabetic nephropathy in Type 2 diabetes has not been studied extensively and it is not yet clear whether the incidence and rate of progression is the same in Type 2 as in Type 1 diabetes. It has been suggested that microalbuminutia in the older non-diabetic population may be a manifestation of widespread atherosclerosis [28] and it remains possible that the association in this study between elevated apo (a) and microalbuminuria in Type 2 diabetes is due to the common link with macrovascular disease. However, development of microalbuminuria in Type t diabetes also predicts an increased risk of cardiovascular disease [29] and has been shown to be associated with elevation of apo (a) levels [7] [8] [9] .
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The link between diabetic renal disease and increased apo (a) levels was reinforced in this study by the finding that log plasma creatinine was a significant predictor of log apo (a) levels. Elevated apo (a) levels have been observed previously in patients with chronic renal failure [14, 30] and have been shown to decrease after renal transplantation [30] . In our study, renal function, as evaluated by plasma urea, creatinine and creatinine clearance, was relatively normal and certainly none of the patients had end-stage renal failure. Although the findings of this study indicate a likely association between apo (a) and diabetic nephropathy, we cannot deduce whether raised apo (a) is an effect of altered renal function, the cause of renal damage, or both.
If elevated apo (a) is due to disturbed renal function, potential mechanisms may involve increased urinary protein loss. In the nephrotic syndrome, urinary protein loss or changes in plasma albumin may trigger increased hepatic production of lipoproteins [31, 32] , and elevated levels of Lp (a) have been reported in patients with heavy proteinuria, but normal creatinine [33] . On the other hand, a role for hyperlipidaemia in chronic renal injury has been postulated [34, 35] . Mechanisms for renal damage by Lp (a) could include enhanced atherosclerosis and microthrombi formation which are recognised histological features of diabetic nephropathy and consistent with the pathophysiological role postulated for Lp (a) [21, 25] .
Longitudinal studies will help to resolve the issue of whether raised Lp (a) is a consequence or a cause of diabetic renal disease. It will be of particular interest to observe whether apo (a) rises with the onset and progression of microalbuminuria and whether measures that reduce urinary albumin loss also reduce apo (a) levels. Alternatively, extensive family studies with phenotyping could be used to establish whether elevated apo (a) is a genetically determined or acquired characteristic of the patients with diabetic nephropathy. Although many questions about the relationship remain unanswered, our preliminary results suggest that apo (a) levels are elevated in Type 2 diabetic patients with renal damage, even at its very early stage of microalbuminuria. Thus, we have identified a further risk factor that may contribute to the well-recognised high risk of vascular disease and early mortality in Type 2 diabetic patients. There is evidence that Lp (a) level is reduced by treatment with niacin, neomycin, omega-3-fatty acids and stanazolol [11, 12] , however, it is not yet known whether such treatment in people with high levels of apo (a) will reduce the incidence of vascular disease.
